Abiopharma

🔍 Hughes Steven George (Executive)

Company: Avidity Biosciences, Inc. (RNA)

Report Date: 2025-08-22

Detailed Transactions and Holdings:

• Acquired 2,208 shares of Common Stock at $10.16 per share (Direct)
  Date: 2025-08-22 | Code: M | equity_swap_involved: 0 | shares_owned_after: 41,075.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,208 shares of Common Stock at $46.4047 per share (Direct)
  Date: 2025-08-22 | Code: S | equity_swap_involved: 0 | shares_owned_after: 38,867.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 2,208 shares of Stock Option (Right to Buy) at $10.16 per share (Derivative)
  Date: 2025-08-22 | Code: M | Expires: 2034-01-19 | equity_swap_involved: 0 | shares_owned_after: 72,875.00 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024.
• F2: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.64 to $47.03. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: This option was granted on January 20, 2024 and vests in equal installments of 2,208 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on January 20, 2028.